MedTrace Logo

STHLM3 AS NorDCaP - a Followup Study of Men on Active Surveillance of Prostate Cancer

NCT04627948 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2025-01-21

No results posted yet for this study

Summary

The aim of the STHLM3 AS NorDCaP study is to evaluate the Stockholm3 test in an active surveillance cohort to predict upgrading on rebiopsy. The study follows a paired design, evaluating our proposed protocol for follow up men on active surveillance with Stockholm3 versus the standard protocol according to national guidelines with PSA.

Conditions

Interventions

DIAGNOSTIC_TEST

Stockholm3 test

Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.

Sponsors & Collaborators

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • University of Aarhus

    collaborator OTHER

  • Mehiläinen, Finland

    collaborator UNKNOWN

  • Capio Sankt Görans Hospital

    collaborator OTHER

  • Karolinska Institutet

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04627948 on ClinicalTrials.gov